A detailed history of Dn B Asset Management As transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Dn B Asset Management As holds 668,137 shares of BMY stock, worth $32.5 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
668,137
Previous 335,550 99.12%
Holding current value
$32.5 Million
Previous $18.2 Million 52.49%
% of portfolio
0.14%
Previous 0.1%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$40.25 - $52.99 $13.4 Million - $17.6 Million
332,587 Added 99.12%
668,137 $27.7 Million
Q1 2024

Apr 12, 2024

SELL
$47.98 - $54.4 $9.2 Million - $10.4 Million
-191,690 Reduced 36.36%
335,550 $18.2 Million
Q4 2023

Jan 04, 2024

SELL
$48.48 - $57.85 $1.5 Million - $1.79 Million
-30,875 Reduced 5.53%
527,240 $27.1 Million
Q3 2023

Oct 13, 2023

BUY
$57.89 - $64.73 $1.97 Million - $2.2 Million
34,015 Added 6.49%
558,115 $32.4 Million
Q2 2023

Jul 06, 2023

BUY
$63.71 - $70.74 $5.93 Million - $6.58 Million
93,054 Added 21.59%
524,100 $33.5 Million
Q1 2023

Apr 20, 2023

SELL
$65.71 - $74.53 $13.3 Million - $15.1 Million
-202,204 Reduced 31.93%
431,046 $29.9 Million
Q4 2022

Jan 12, 2023

SELL
$68.48 - $81.09 $501,752 - $594,146
-7,327 Reduced 1.14%
633,250 $45.6 Billion
Q3 2022

Oct 11, 2022

SELL
$0.13 - $76.84 $1,444 - $853,615
-11,109 Reduced 1.7%
640,577 $45.5 Million
Q2 2022

Jul 08, 2022

BUY
$72.62 - $79.98 $674,204 - $742,534
9,284 Added 1.45%
651,686 $50.2 Billion
Q1 2022

Apr 08, 2022

BUY
$61.48 - $73.72 $4.96 Million - $5.95 Million
80,645 Added 14.36%
642,402 $46.9 Million
Q4 2021

Jan 12, 2022

SELL
$53.63 - $62.52 $1.25 Million - $1.46 Million
-23,319 Reduced 3.99%
561,757 $35 Million
Q3 2021

Oct 15, 2021

BUY
$59.17 - $69.31 $1.6 Million - $1.88 Million
27,106 Added 4.86%
585,076 $34.6 Million
Q2 2021

Jul 06, 2021

BUY
$61.91 - $67.42 $554,713 - $604,083
8,960 Added 1.63%
557,970 $37.3 Billion
Q1 2021

Apr 15, 2021

BUY
$59.34 - $66.74 $81,414 - $91,567
1,372 Added 0.25%
549,010 $34.7 Million
Q4 2020

Jan 19, 2021

SELL
$57.74 - $65.43 $7.29 Million - $8.26 Million
-126,287 Reduced 18.74%
547,638 $34 Million
Q3 2020

Oct 14, 2020

SELL
$57.43 - $63.64 $842,612 - $933,726
-14,672 Reduced 2.13%
673,925 $40.6 Million
Q2 2020

Jul 08, 2020

BUY
$54.82 - $64.09 $10.9 Million - $12.8 Million
199,203 Added 40.7%
688,597 $40.5 Billion
Q1 2020

Apr 17, 2020

SELL
$46.4 - $67.43 $48.6 Million - $70.7 Million
-1,047,863 Reduced 68.16%
489,394 $27.3 Million
Q4 2019

Jan 13, 2020

BUY
$49.21 - $64.19 $60.5 Million - $79 Million
1,229,945 Added 400.23%
1,537,257 $98.7 Million
Q3 2019

Oct 16, 2019

SELL
$42.77 - $50.71 $5.77 Million - $6.84 Million
-134,794 Reduced 30.49%
307,312 $15.6 Million
Q2 2019

Jul 08, 2019

SELL
$44.62 - $49.34 $20,435 - $22,597
-458 Reduced 0.1%
442,106 $0
Q1 2019

Apr 11, 2019

SELL
$45.12 - $53.8 $7.08 Million - $8.44 Million
-156,836 Reduced 26.17%
442,564 $0
Q4 2018

Jan 15, 2019

BUY
$48.76 - $63.23 $12 Million - $15.5 Million
245,435 Added 69.34%
599,400 $31.2 Million
Q3 2018

Oct 10, 2018

BUY
$55.19 - $62.25 $1.78 Million - $2 Million
32,203 Added 10.01%
353,965 $0
Q2 2018

Jul 06, 2018

BUY
$50.53 - $62.98 $45,477 - $56,682
900 Added 0.28%
321,762 $0
Q1 2018

Apr 11, 2018

SELL
$59.92 - $68.98 $2.79 Million - $3.21 Million
-46,500 Reduced 12.66%
320,862 $0
Q4 2017

Jan 10, 2018

SELL
$59.94 - $65.35 $4.11 Million - $4.48 Million
-68,544 Reduced 15.72%
367,362 $0
Q3 2017

Oct 11, 2017

BUY
$55.23 - $63.74 $24.1 Million - $27.8 Million
435,906
435,906 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $104B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Dn B Asset Management As Portfolio

Follow Dn B Asset Management As and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.